Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis Noninvasive Imaging Compared to Endomyocardial Biopsy by Vogelsberg, Holger et al.
I
a
i
s
o
f
d
t
F
a
G
fi
2
Journal of the American College of Cardiology Vol. 51, No. 10, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PCardiovascular Magnetic Resonance
in Clinically Suspected Cardiac Amyloidosis
Noninvasive Imaging Compared to Endomyocardial Biopsy
Holger Vogelsberg, MD,* Heiko Mahrholdt, MD,* Claudia C. Deluigi, MD,* Ali Yilmaz, MD,*
Eva M. Kispert, RN,* Simon Greulich, MD,* Karin Klingel, MD,† Reinhard Kandolf, MD,†
Udo Sechtem, MD*
Stuttgart and Tuebingen, Germany
Objectives We sought to evaluate the diagnostic performance of cardiovascular magnetic resonance imaging (CMRI) for
detection of cardiac amyloidosis compared with endomyocardial biopsy (EMB) in a clinical routine setting.
Background For the clinical workup of heart failure with restrictive filling, pattern cardiac amyloidosis is an important differ-
ential diagnosis that is difficult to verify with current noninvasive techniques, especially in the presence of myo-
cardial hypertrophy.
Methods A total of 33 consecutive patients underwent both CMRI and EMB for workup of heart failure with restrictive fill-
ing pattern in combination with myocardial hypertrophy (n  24) and/or clinical conditions often associated with
cardiac amyloidosis (n  18).
Results Cardiac amyloidosis was detected by EMB in 15 of the 33 patients. In patients with biopsy-proven cardiac amy-
loidosis, CMRI revealed a distinct pattern of late gadolinium enhancement, which was distributed over the entire
subendocardial circumference, extending in various degrees into the neighboring myocardium. This pattern was
found in 12 of the 15 patients diagnosed with cardiac amyloidosis by EMB, compared with only 1 individual in
the group of 18 patients diagnosed with other myocardial diseases. Consequently, using this pattern as a diag-
nostic criterion, the sensitivity of CMRI for diagnosing cardiac amyloidosis was 80%, yielding a specificity of
94%. The positive predictive value was 92%, and the negative predictive value was 85%.
Conclusions In patients with biopsy-proven cardiac amyloidosis, late gadolinium enhancement frequently occurs in a peculiar
pattern. On the basis of the gold standard, EMB, noninvasive CMRI can be used to diagnose or rule out cardiac
amyloidosis with good sensitivity and excellent specificity in a clinical routine setting. (J Am Coll Cardiol 2008;
51:1022–30) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.049e
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cn the clinical workup of patients with diastolic heart failure
nd myocardial hypertrophy, cardiac amyloidosis is an
mportant differential diagnosis (1). Effective treatments for
See page 1031
ome forms of cardiac amyloidosis exist, but treatment
ptions are extremely limited once severe symptoms of heart
ailure become clinically apparent. Consequently, the early
iagnosis of cardiac amyloidosis may significantly improve
he clinical outcome (1).
rom the *Division of Cardiology, Robert Bosch Medical Center, Stuttgart, Germany;
nd the †Department of Molecular Pathology, University of Tuebingen, Tuebingen,
ermany. The first 2 authors contributed equally to this article and they both share
rst authorship of this article.s
Manuscript received July 16, 2007; revised manuscript received September 24,
007, accepted October 31, 2007.The gold standard for diagnosing cardiac amyloidosis is
ndomyocardial biopsy (EMB) (2), but this technique is
nvasive, limited to experienced centers, and thus not widely
vailable. Hence, in clinical practice, the diagnosis of cardiac
myloidosis rests mainly on echocardiographic findings,
upported by the clinical history, and a diagnostic noncar-
iac biopsy (3,4). However, diagnosis by echocardiography
as limitations (5), particularly if hypertrophy from other
auses is present. Other noninvasive methods also have
imitations (6), including electrocardiography (7) or scinti-
raphic techniques (8,9).
Recent pilot data (10,11) suggest that noninvasive car-
iovascular magnetic resonance imaging (CMRI) using late
adolinium enhancement (LGE) may be a valuable tool for
iagnosing cardiac amyloidosis. This technique has proven
linical value for noninvasive tissue characterization in
everal cardiac diseases (12) and may overcome many
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March 11, 2008:1022–30 CMRI in Cardiac Amyloidosisimitations of other noninvasive methods in the clinical
etting of suspected cardiac amyloidosis (13).
Consequently, we sought to evaluate the diagnostic per-
ormance of CMRI for detection of cardiac amyloidosis
ompared with the gold-standard EMB in a routine clinical
etting in consecutive patients admitted for workup of heart
ailure with restrictive filling pattern in combination with
yocardial hypertrophy and/or conditions often associated
ith cardiac amyloidosis.
ethods
atient population. Between 2003 and 2006, 33 consecu-
ive patients underwent both CMRI and EMBs for workup
f heart failure with restrictive filling pattern in combination
ith myocardial hypertrophy (n  24) and/or conditions
ften associated with cardiac amyloidosis (n  18) such as
ystemic amyloidosis (n  4), multiple myeloma (n  5),
ymphoma (n  2), end-stage renal failure (n  3), or other
onditions (n  4). To allow evaluation of the diagnostic
erformance of CMRI in a clinical routine setting, patients
ith dyspnea at rest, atrial fibrillation, ventricular arrhyth-
ias, and other frequent cardiac disorders such as coronary
rtery disease were not excluded. All patients gave written
nformed consent and were included in the study.
MRI protocol. Electrocardiographically gated CMRI
as performed in breath-hold using a 1.5-T Magnetom
onata (Siemens Medical Systems, Erlangen, Germany).
oth cine and LGE short-axis CMRI were prescribed every
Figure 1 Multiple Contrast CMRI of the Same Short-Axis View
Different TI Acquired Beginning at 4 Min After Contra
At inversion time (TI)  80 ms, all structures are below the null point and appear
lar (LV) myocardium (white arrows) goes through the null point earlier than the LV
region (subendocardial circumference and right ventricle) is obviously not a corona
such as cardiac amyloid (high signal at 240 ms). The myocardium surrounding this
framed image). CMRI  cardiovascular magnetic resonance imaging.0 mm (slice thickness 6 mm)
rom base to apex. In-plane res-
lution was typically 1.2 
.8 mm. Cine CMRI was per-
ormed using a steady-state free-
recession sequence. The LGE
mages were acquired on average
min (10) after administrating
adodiamide 0.1 mmol/kg (Omni-
can, Amersham-Health, Braun-
chweig, Germany) using a seg-
ented inversion recovery gradient echo technique, constantly
djusting the inversion time to null normal myocardium (14).
n addition, fat-saturated and T2-weighted images were ob-
ained to allow differentiation among subepicardial LGE,
picardial fat, and pericardial effusion.
In cardiac amyloidosis, however, it may be difficult to
etermine the optimal inversion time that will null normal
yocardium, as it may be unclear which myocardial areas
re normal (10). Thus, we first acquired multiple images of
he same view using different inversion times. If a large
ortion of left ventricular myocardium (i.e., 50%) goes
hrough the null point earlier than the left ventricular cavity
nd this region is not in an obvious coronary artery
istribution territory, this area is highly likely to represent
yocardial disease such as cardiac amyloid. Consequently,
he inversion time was then adjusted to null the remaining
yocardial areas (Fig. 1).
ection
n the image. At TI  120 ms, a large portion of the subendocardial left ventricu-
, which crosses the null point at a TI of 200 ms (white circle). Because this
ry distribution territory, this area is highly likely to represent myocardial disease
n is likely to be normal, as it is nulled at a TI of 240 ms (white arrows in black
Abbreviations
and Acronyms
CMRI  cardiovascular
magnetic resonance
images/imaging
EMB  endomyocardial
biopsy
LGE  late gadolinium
enhancementUsing
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CMRI in Cardiac Amyloidosis March 11, 2008:1022–30MRI analysis. Cine and contrast images were evaluated
eparately by 2 blinded observers as described elsewhere
15,16). In brief, endocardial and epicardial borders were
utlined on the short-axis cine images. Volumes, myocardial
ass, and ejection fraction were derived by summation of
picardial and endocardial contours.
Regional parameters were assessed, dividing each short
xis into 12 circumferential segments (Fig. 2). For each
egment, the extent of LGE was analyzed using the NIH
mage analysis software package (National Institutes of
ealth, Bethesda, Maryland), and the results were
xpressed as a percentage of the area of the outer, middle,
nd inner third of each segment.
yocardial biopsy protocol. At least 5 endomyocardial
iopsies were taken from the region showing LGE, as
escribed elsewhere (16). In patients without the presence
f LGE, at least 4 biopsies were taken from the right
entricle (septum) and usually also another 4 biopsies from
eft ventricular lateral wall to minimize sampling errors.
istopathological analysis. The EMBs were stained with
asson’s trichrome and examined by light microscopy.
ardiac amyloidosis was diagnosed using Congo red stain-
ng by demonstration of the typical green birefringence
nder cross-polarized light. Additionally, electron micros-
opy for visualization of amyloid deposits was performed to
ule out Congo red negative amyloidosis (Fig. 2).
To diagnose/exclude inflammatory heart disease, paraffin
issue sections were treated with an avidin-biotin immuno-
eroxidase method (Vectastain-Elite ABC Kit, Vector,
urlingame, California) with application of the following
onoclonal antibodies: CD3 (T-cells, Novocastra Labora-
ories, Newcastle, United Kingdom), CD68 (macrophages,
atural killer cells, DAKO, Hamburg, Germany), and
E
M
B
W
O
R
K
U
P
L
G
E
A
na
ly
si
s
A B
**
Figure 2 Contrast Short-Axis CMRI and EMB Work Up of Patie
(Top row) Contrast short-axis CMRI of Patient #17 (basal slice on the left with sub
between slices; TI  220 ms). For contrast CMRI analysis, each short-axis image
the upper row. (Bottom row) Histopathological workup of endomyocardial biopsy (
loid deposits (arrows) between myocytes (A), Congo red staining (B) with demons
electron microscopy visualizing amyloid deposits between myocytes expanding the
tions as in Figure 1.LA-DR-alpha (DAKO). Myocardial inflammation
ndicative of myocarditis was defined as the detection of
14 infiltrating leukocytes/mm2 (CD3 T lymphocytes
nd/or CD68 macrophages) (17).
tatistical analysis. Data for continuous variables are ex-
ressed as mean value  SD, whereas data for categorical
ariables are expressed as the number and the percentage of
atients. Comparisons between groups were done using a
-tailed unpaired Student t test for normally distributed and
ann-Whitney U test for non-normally distributed con-
inuous variables. For categorical variables, we used the
hi-square test and Fisher exact test where appropriate. The
ifference between 2 groups was defined to be statistically
ignificant if the 2-tailed p value was 0.05.
The authors had full access to the data and take respon-
ibility for its integrity. All authors have read and agree to
he manuscript as written.
esults
atient characteristics. All patients presented with various
egrees of dyspnea limiting their exercise tolerance (n 29)
r experienced dyspnea at rest (n  4). Three patients
eported atypical chest pain, and 3 other patients had atrial
brillation. Most patients did not have evidence for systemic
myloidosis upon presentation, except 4 in whom systemic
myloidosis was demonstrated by noncardiac biopsy. Nine
atients had significant coronary artery disease, defined as
oronary artery stenosis 50% in diameter. All patients
ith coronary artery disease had already been revascularized
f possible and were receiving appropriate medication. On
he basis of coronary angiography at the time point of EMB,
dditional coronary intervention was not indicated in any of
C D E
7
nt 6-mm slices toward the apex shown to the right; there is a 4-mm gap
vided into 12 circumferential segments by applying a grid, as demonstrated in
amples for cardiac amyloidosis included Masson’s trichrome staining with amy-
of typical red/green birefringence () under cross-polarized light (C), as well as
ellular volume (D and E). LGE  late gadolinium enhancement; other abbrevia-nt #1
seque
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March 11, 2008:1022–30 CMRI in Cardiac Amyloidosishese patients. Other clinical characteristics of all patients
an be viewed in Table 1.
istopathological results. The EMB was performed
ithout complications in all 33 patients. In 15 patients,
ardiac amyloidosis was identified by histopathological
orkup as described earlier. In the remaining 18 patients,
MB revealed myocarditis (n  6), secondary left ventric-
lar hypertrophy (n  5), hypertrophic cardiomyopathy
n  4), or combinations of those entities, as displayed in
able 1. In 1 patient (Patient #18), small amounts of
onspecific interstitial myocardial fibrosis were detected, but
o definite diagnosis could be made.
In the group of patients with significant coronary artery
isease (n 9), cardiac amyloidosis was detected in 3 patients,
hich was not significantly different from all patients without
atient Characteristics
Table 1 Patient Characteristics
Patient # Age (yrs) EF (%) EDV (ml) IVS Max (mm) L
1 55 66 64 15
2 76 45 165 20
3 50 68 171 17
4 68 66 116 9
5 64 39 185 13
6 79 69 121 11
7 72 62 139 22
8 69 69 137 21
9 74 50 102 22
10 68 48 111 13
11 80 83 103 11
12 68 65 76 12
13 76 72 138 22
14 44 56 107 13
15 52 40 85 17
16 72 69 111 18
17 64 36 191 18
18 77 61 125 10
19 65 57 150 20
20 70 72 116 10
21 62 37 228 10
22 34 49 208 16
23 62 39 105 14
24 84 57 163 14
25 68 87 134 14
26 34 49 108 15
27 47 30 54 15
28 71 60 143 19
29 44 77 84 13
30 47 72 100 16
31 61 55 201 9
32 67 62 112 16
33 81 27 128 10
All 64  13 57  15 130  41 15  4
ll  average or percentage; AMYLO  amyloidosis; Amyloid LGE Pattern  diffuse subendocardi
jection fraction; EMB  endomyocardial biopsy; HCM  hypertrophic cardiomyopathy; IVS  int
entricular hypertrophy; Max  maximum; MYO  myocarditis; N/A  not applicable; PAP LGE oronary artery disease (p 0.5). All 4 patients with known 3ystemic amyloidosis also had evidence of cardiac amyloid-
sis by EMB.
MRI results. We performed CMRI in all 33 patients,
ncluding 4 patients with dyspnea at rest and 3 patients with
trial fibrillation. Although breathing and trigger artifacts
ccurred more frequently in those 7 patients, image quality
as sufficient for analysis in all 33 patients. Late gadolinium
nhancement was present in 26 of the 33 patients (79%).
aseline CMRI characteristics such as ejection fraction,
nd-diastolic volume, ventricular mass, and maximum ven-
ricular wall thickness can be viewed in Table 1.
Several different patterns of LGE were present in this
atient population. In 13 patients, LGE was distributed
ver the entire subendocardial circumference, extending
n various degrees into the neighboring myocardium (Fig.
s (g) LGE (Y/N) PAP LGE (Y/N)
Amyloid LGE
Pattern (Y/N) EMB Result
6 1 1 1 AMYLO
6 1 1 1 AMYLO
4 1 0 0 LVHMYO
8 0 0 0 LVH
8 1 0 0 MYO
5 0 0 0 LVH
2 1 1 1 AMYLO
4 1 1 1 AMYLO
6 1 1 1 AMYLO
3 1 0 0 MYO
4 1 0 0 LVH
1 1 0 0 LVH
9 1 1 1 AMYLO
7 0 0 0 HCM
5 1 1 0 HCM
6 1 0 0 AMYLO
3 1 1 1 AMYLO
6 0 0 0 UNCLEAR
4 1 0 0 LVH
5 1 0 0 MYO
2 0 0 0 MYO
2 1 1 1 HCM
1 1 0 0 MYO
1 1 1 1 AMYLO
3 0 0 0 MYO
1 1 0 0 MYOLVH
1 1 0 1 AMYLO
6 1 1 1 AMYLO
4 1 1 1 AMYLO
0 1 1 1 AMYLO
3 1 0 0 AMYLO
5 1 0 0 HCM
8 0 0 0 AMYLO
62 79% 39% 39% N/A
adolinium enhancement distribution, as displayed in Figure 4; EDV  end-diastolic volume; EF 
icular septum; LGE  late gadolinium enhancement; LV  left ventricular; LVH  secondary left
dolinium enhancement in papillary muscles.V Mas
11
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CMRI in Cardiac Amyloidosis March 11, 2008:1022–30he left interventricular septum, often originating from
he right ventricular insertion points (Fig. 4), as well as
ubepicardial LGE, located mainly in the left ventricular
Figure 3 Typical Contrast CMRI of 2 Patients Diagnosed With
In both patients, LGE was diffusely distributed in large areas of the left ventricle in
subepicardial myocardium is affected only in areas of transmural LGE. Note that L
include Mason’s trichrome with amyloid deposits between myocytes (black arrows
green birefringence under cross-polarized light. Abbreviations as in Figures 1 and 2
P
at
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Contrast CMR Ima
Figure 4 Typical Contrast CMRI of 2 Patients Diagnosed With
One patient demonstrated focal intramural LGE at the right ventricular insertion po
TI  320 ms). This diagnosis was confirmed by histopathology demonstrating myo
staining (blue areas between myocytes, black arrows). Note that LGE is also pres
patient was diagnosed with myocarditis exhibiting enhanced numbers of interstitia
PVB19 in the myocardium. The white arrows in the bottom panel point to typical
pattern of LGE found in these patients is completely different from the LGE pattern
Abbreviations as in Figures 1 and 2.ateral wall, in 4 patients (Fig. 4). The remaining patients had
ocal areas of LGE in various locations of the left ventricular
yocardium. Late gadolinium enhancement located in the
ac Amyloidosis by EMB
g the entire subendocardium (TI  230 ms in both patients). Interestingly, the
also located in the papillary muscles (white arrowheads). Histologic images
right panels) and Congo red staining (inset right panels) demonstrating typical
Trichrome
Myocardial Diseases
hich is a typical finding in hypertrophic cardiomyopathy (top row, white arrows,
ypertrophy (red cells) and interstitial fibrosis as shown by Masson’s trichrome
the inferior papillary muscle in this patient (thin white arrow). The second
 macrophages as well as interstitial edema. Molecular pathology revealed
cardial LGE in the left ventricular inferolateral wall (TI  300 ms). Note that the
is usually present in patients with biopsy proven cardiac amyloidosis (Fig. 3).Cardi
volvin
GE is
, large
.ging
Other
ints, w
cyte h
ent in
l CD68
subepi
that
p
3
C
p
c
e
d
T
1
E
p
p
d
p
c
t
n
g
i
p
h
m
t
d
t
8
e
v
T
D
T
C
d
E
d
(
o
g
H
w
a
d
h
i
f
m
LV
S
p
1027JACC Vol. 51, No. 10, 2008 Vogelsberg et al.
March 11, 2008:1022–30 CMRI in Cardiac Amyloidosisapillary muscles could be observed in 13 of 33 patients (Figs.
and 4).
omparing cardiac amyloidosis patients with all other
atients. In the group of patients with biopsy-proven
ardiac amyloidosis, LGE was typically distributed over the
ntire subendocardial circumference, extending in various
egrees into the neighboring myocardium (Figs. 3 and 5).
his pattern (amyloid LGE pattern) (Fig. 5) was found in
2 of the 15 patients diagnosed with cardiac amyloidosis by
MB, compared with only 1 individual in the group of 18
atients diagnosed with other myocardial diseases (Table 2).
In addition to presentation with amyloid LGE pattern,
atients with cardiac amyloidosis were much more likely to
emonstrate LGE in the papillary muscles than were
atients without cardiac amyloidosis (Table 2). All other
linical characteristics, including ejection fraction, left ven-
ricular end-diastolic volume, and myocardial mass, were
Figure 5 Spatial Distribution of LGE in
Patients With and Without Amyloid
Spatial distribution of the mean values for segmental extent of LGE values are
represented as gray-scale maps in basal, mid-, and apical short-axis slices in
all patients diagnosed with cardiac amyloidosis by endomyocardial biopsy (top
row) and all other patients (bottom row). In patients with biopsy-proven car-
diac amyloidosis, LGE is typically distributed diffusely in large areas of the left
ventricle, mainly involving the subendocardial area circumferentially, whereas
the subepicardial myocardium is less affected. Abbreviations as in Figure 2.
Comparison of Patients With Cardiac Amyloidos
Table 2 Comparison of Patients With Cardia
Amyloidosis (n  15) Ot
Age (yrs) 66 13
EF (%) 56 16
EDV (ml) 128 43
IVS max (mm) 17 4
LV mass (g) 188 59
LGE (n) 14 (93%)
PAP LGE (n) 11 (80%)
Amyloid LGE pattern (n) 12 (80%)
Bold indicates statistical significance; 2-tailed p value 0.05.
Amyloid LGE pattern  diffuse subendocardial LGE distribution, as displaye
test); other abbreviations as in Table 1.ot significantly different between the cardiac amyloidosis
roup and all other patients, except the thickness of the
nterventricular septum (Table 2). Interestingly, all 3
atients initially presenting with atrial fibrillation did not
ave cardiac amyloidosis by EMB. One was diagnosed with
yocarditis, 1 with secondary left ventricular hypertrophy in
he setting of hypertension, and 1 with hypertrophic car-
iomyopathy.
Using the amyloid LGE pattern as a diagnostic criterion,
he sensitivity of CMRI to detect cardiac amyloidosis was
0% compared with the gold-standard EMB, yielding an
xcellent specificity of 94%. Positive and negative predictive
alues of typical amyloid LGE pattern are displayed in
able 3.
iscussion
his study is unique in that the diagnostic performance of
MRI for detection of cardiac amyloidosis is evaluated by
irect comparison of CMRI results to the gold-standard
MB in clinical routine patients. Our data indicate a
istinct LGE distribution pattern in cardiac amyloidosis
Fig. 5) that can be used to noninvasively diagnose or rule
ut cardiac amyloidosis in a clinical routine setting with
ood sensitivity (80%) and excellent specificity (94%).
istopathological results. Using EMB as a gold standard,
e could identify 15 individuals with cardiac amyloidosis
mong our group of patients presenting for workup of
iastolic heart failure and/or myocardial hypertrophy. This
igh prevalence of 45% is most likely explained by our
nclusion criteria, because in addition to signs of heart
ailure with restrictive filling pattern, most patients had
yocardial hypertrophy (n  24) and/or had conditions
rsus Other Patients
yloidosis Versus Other Patients
n  18) p Value OR 95% CI (OR  1)
14 0.26 — —
15 0.96 — —
42 0.93 — —
3 0.011 — —
66 0.31 — —
61%) 0.05 8.38 0.9–428.5
11%) 0.0004 19.29 2.7–248.2
(5%) 0.000014 54.73 5.3–2,993.9
ate Gadolinium Enhancementersus Endomyocardial Biopsy
Table 3 Late Gadolinium EnhancementVersus Endomyocardial Biopsy
Amyloid LGE Pattern No/Other LGE All
Cardiac amyloid by EMB 12 3 15
Other patients 1 17 18
All 13 20 33
ensitivity (LGE)  80%; specificity (LGE)  94%; positive predictive value (LGE) 92%; negative
redictive value (LGE)  85%.
Abbreviations as in Table 1.is Ve
c Am
hers (
62
58
130
13
166
11 (
2 (
1d in Figure 5; CI  confidence interval; OR  odds ratio (Fisher exact
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CMRI in Cardiac Amyloidosis March 11, 2008:1022–30ften associated with cardiac amyloidosis (n  18), such as
ystemic amyloidosis (n  4), multiple myeloma (n  5),
ymphoma (n  2), end-stage renal failure (n  3), or
thers (n  4).
The EMB revealed cardiac amyloidosis in all 4 patients
ith known systemic amyloidosis. In the presence of dia-
tolic heart failure and hypertrophy in those patients, this
nding is not surprising. However, in 11 of the remaining
9 patients without any evidence of systemic amyloidosis,
MB also revealed cardiac amyloidosis. This suggests that
ardiac amyloidosis without any evidence of systemic amy-
oidosis might occur more frequently than currently sus-
ected (18). This would be of clinical importance, because
n the clinical routine the diagnosis of cardiac amyloidosis is
ade only if a noncardiac biopsy shows amyloid and
chocardiography demonstrates a pattern suggestive of car-
iac involvement (3,4). Thus, if cardiac amyloidosis can
requently occur without systemic amyloidosis, an unknown
umber of patients with cardiac amyloidosis might remain
ndiagnosed until severe symptoms of heart failure of
nknown origin force them to undergo EMB. Because
reatment options are extremely limited once severe symptoms
f heart failure become clinically apparent, the early identifi-
ation of those patients may significantly improve their clinical
utcome (1).
In the remaining 18 patients without any histological evi-
ence of cardiac or systemic amyloidosis, the most frequent
iagnosis was myocarditis, followed by secondary left ventric-
lar hypertrophy and hypertrophic cardiomyopathy (Table 1).
ne would expect a relatively high prevalence of secondary
ypertrophy and hypertrophic cardiomyopathy in elderly pa-
ients presenting with diastolic heart failure (19), but the high
revalence of myocarditis in our patient population is some-
hat surprising. However, this finding may be explained by
facts: first, myocarditis is also known to cause diastolic
eart failure (20), which was an inclusion criteria for this
tudy; second, the general prevalence of myocarditis might
e underestimated because the clinical diagnosis of myocar-
itis is often difficult to achieve (21,22).
MRI results. Late gadolinium enhancement was present
n 79% of patients, indicating that LGE is a frequent
nding in clinical routine patients presenting for workup of
eart failure with restrictive filling pattern in combination
ith myocardial hypertrophy and/or conditions often asso-
iated with cardiac amyloidosis.
In the group with biopsy-proven cardiac amyloidosis, we
ound a distinct pattern of myocardial LGE. Twelve of the
5 patients had LGE distributed over the entire subendo-
ardial circumference, extending in various degrees into the
eighboring myocardium (Figs. 3 and 5). This finding is in
ine with the report of Maceira et al. (10) describing a
ubstantially lower T1 relaxation time in the subendocar-
ium of patients with cardiac amyloidosis after administra-
ion of gadolinium using a T1 mapping CMRI technique.
owever, our finding of a distinct “amyloid LGE pattern”
ontradicts the conclusions of Perugini et al. (11) that theistribution of LGE in cardiac amyloidosis is highly vari-
ble. This discrepancy may be explained by the fact that
erugini et al. (11) started the acquisition of contrast images
0 to 15 min after gadolinium injection. Because LGE in
ardiac amyloidosis fades with equalization of T1 between
he subendocardium and subepicardium approximately 8
in after gadolinium injection owing to altered contrast
gent kinetics (10), the late start of image acquisition at 15
in after gadolinium administration might have signifi-
antly affected imaging results in the study of Perugini et al.
11).
Importantly, the distinct pattern of LGE in cardiac
myloidosis, as described in the current study, may be
xplained by the uneven transmural distribution of amyloid
een in necropsy. Becker et al. (23) reported that cardiac
myloid deposits are predominantly located diffusely in the
ubendocardial region and that they may even produce a
sandy sensation” when the formalin-fixed subendocardial
rea is palpated during post-mortem examination (23).
aceira et al. (10) also found a subendocardially pro-
ounced distribution of amyloid protein in their study
subendocardium 42.4%, subepicardium 17.6%). Because
myloidosis causes accumulation of abnormal interstitial
rotein, resulting in an enlargement of the extracellular
pace, it is highly likely that on the basis of the general
echanism of LGE (12), amyloid deposits alone will result
n LGE in the absence of significant myocardial fibrosis or
ecrosis. However, if amyloid deposits result in LGE, it
onceptually follows that the pattern of LGE in patients
ith cardiac amyloidosis is supposed to match the distribu-
ion of cardiac amyloid protein demonstrated post-mortem.
igure 6 compares a long-axis contrast CMRI from a
atient included in this study to a necropsy image from a
ifferent cardiac amyloidosis patient published by Becker et
l. (23). The typical diffuse LGE affecting the subendocar-
Contrast CMR in patient 2 Necropsy from Becker AE and Anderson HR
Figure 6 Contrast Long-Axis CMR Compared to Necroscopy
Long-axis contrast CMRI (Left) patient #2 (TI  230 ms). (Right) necropsy
sample of a different patient diagnosed with cardiac amyloidosis. Interestingly,
the pattern of diffuse LGE originating from the subendocardium nicely matches
the pattern of pale subendocardial amyloid deposits indicated by white arrow-
heads in the necropsy sample. Right panel adapted with permission from (23).
Abbreviations as in Figures 1 and 2.
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March 11, 2008:1022–30 CMRI in Cardiac Amyloidosisial areas nicely matches the pale subendocardial regions of
myloid deposits in the necropsy case.
However, despite this match between LGE and the
istribution of amyloid seen in necropsy, it needs to be kept
n mind that in the present study 3 patients with biopsy-
roven cardiac amyloidosis did not demonstrate this typical
amyloid LGE pattern” (Patients #16, #31, and #33).
atient #31 had significant left anterior descending artery
tenosis, and CMRI showed typical subendocardial LGE in
he left anterior descending artery territory indicative of
ontransmural myocardial infarction. In this patient, EMB
evealed only very small amounts of cardiac amyloid due to
ultiple myeloma. Thus, this very small amount of cardiac
myloid was most probably beyond the spatial resolution of
MRI (12), which typically was about 1.2  1.8 mm in
lane. This mechanism may also explain the absence of any
GE in Patient #33. Patient #16 had patchy subendocardial,
s well as diffuse intramural posterolateral LGE, maybe reflect-
ng heterogeneous cardiac amyloid deposition, as reported to
ccur in some patients by post-mortem exam (24).
Interestingly, in 1 other patient (Patient #22) in whom
he typical LGE pattern of cardiac amyloidosis was present,
o evidence of cardiac or systemic amyloidosis could be
ound by histopathology. One possible explanation for this
nding might be that the “amyloid LGE pattern” may also
ccur in other myocardial diseases. However, it is also
ossible that Patient #22 was erroneously assigned to the
no amyloidosis” group because of a sampling error in
ndomyocardial biopsies. In fact, the clinical history of this
atient with a systemic disease, hepatomegaly, as well as
chocardiographic and CMRI findings would be much
ore indicative of cardiac amyloidosis than of hypertrophic
ardiomyopathy, as suggested by EMB.
omparing cardiac amyloidosis patients with all other
atients. Comparing patients with biopsy-proven cardiac
myloidosis with patients without amyloidosis, we did not
nd a significant difference in left ventricular ejection
raction, end-diastolic volume, or myocardial mass (Table
). These data, furthermore, underscore the difficulties of
iagnosing cardiac amyloidosis based on morphological or
unctional features. Interestingly, the average thickness of
he interventricular septum was significantly different be-
ween the groups. Patients with cardiac amyloidosis had an
verage septal thickness of 17 4 mm compared with 13
mm in nonamyloid patients, which is consistent with
chocardiographic data (25). In the clinical routine, how-
ver, this sign is not helpful in making the diagnosis of
ardiac amyloidosis, because advanced patient age (64  13
ears in the present study) and common comorbidities such
s hypertension render septal ventricular hypertrophy
onspecific to the underlying disease process (5,13,19).
oreover, cardiac amyloidosis can be present in patients
ithout any septal hypertrophy (e.g., Patients #31 and
33 in Table 1).
In the present study, the incidence of LGE located withinhe papillary muscles was significantly higher in patients rith cardiac amyloidosis than in all other patients (Table 2).
his finding is consistent with post-mortem data (23)
eporting amyloid deposits in the entire subendocardial
egion, including the papillary muscles. Some authors (26)
ave also described the papillary muscles to be “more dense
han normal” on echocardiographic images as an additional
eature of myocardial “sparkling” observed by echocardiog-
aphy in cardiac amyloidosis patients. However, changes in
chocardiographic technology have rendered this finding
ess noticeable in the current clinical routine (25). In the
resent study, papillary LGE was almost always seen in
ombination with “amyloid LGE pattern” except for 2 cases
f hypertrophic cardiomyopathy (Patients #15 and #22)
Fig. 4). Thus, the role of papillary LGE for the diagnosis
f cardiac amyloidosis needs to be further investigated.
linical implications. On the basis of our findings, non-
nvasive CMRI can be used to identify patients with cardiac
myloidosis with good sensitivity and excellent specificity
ompared with the gold-standard EMB. Importantly, this
as shown in a clinical routine setting, because patients with
yspnea at rest, atrial fibrillation, and other frequent cardiac
isorders such as coronary artery disease were not excluded.
hus, in the future it may be possible to establish the
iagnosis of cardiac amyloidosis on the basis of clinical
riteria in combination with the presence of the “amyloid
GE pattern.” In those patients, treatment may be initiated
ithout the need for EMB, except if the exact type of
myloid is needed for therapy planning. However, if no
amyloid LGE pattern” is present, EMB will probably
emain necessary to detect “CMRI-negative” amyloidosis or
ther myocardial pathology.
Although still a small sample, the data of the present
tudy point to a lower index of suspicion required to
egin the search for amyloid with this new technique.
his is also underscored by the fact that our data suggest
hat cardiac amyloidosis might occur more frequently
ithout any evidence of systemic amyloidosis than cur-
ently suspected.
Nevertheless, before any evidence-based clinical recommen-
ations can be made, all these findings need to be further
nvestigated in a larger patient population and a multicenter
etting.
In addition to the diagnosis of cardiac amyloidosis itself,
ontrast CMRI provides direct information on the spatial
istribution of cardiac amyloid protein in the myocardium
nd thus might be proven useful by further investigations to
onitor progression or regression of cardiac amyloid de-
ositions, with or without therapy. However, because of
ecent reports of nephrogenic systemic fibrosis (27), the use
f gadolinium-based contrast agents may be limited in
atients with severe renal problems. This also needs further
nvestigation, as well as the question whether CMRI tech-
iques without gadolinium-based contrast agents may be
elpful in identifying cardiac amyloidosis in the subgroup of
enal patients.
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n the basis of the gold-standard EMB, noninvasive CMRI
an be used to diagnose or rule out cardiac amyloidosis with
ood sensitivity and excellent specificity in a clinical routine
etting. In patients with biopsy-proven cardiac amyloidosis,
GE frequently occurs in a peculiar pattern, diffusely distrib-
ted over the entire subendocardial circumference and extend-
ng in various degrees into the neighboring myocardium. This
attern may directly reflect the spatial distribution of amyloid
rotein in the myocardium.
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